2016 Symposium: We Have Reached the Tipping Point
The momentum at the Foundation’s 5th International Focused Ultrasound Symposium demonstrates the progression of the technology from a research tool toward a viable clinical treatment. From the record number of investigators attending, to the quantity and quality of clinical trials reported, to the celebration of the first FDA approvals of clinical brain and prostate systems, the meeting ushered in a new era.
The symposium featured more than 200 presentations, including updates on 15 clinical trials. Topics included the use of FUS for movement disorders, psychiatric disorders, brain tumors and other cancers, bone and soft tissue diseases, women’s health, cardiovascular conditions, and emerging applications. More than 400 people attended.
|"Four different groups and companies approached me for new collaborations. You know how to get people excited about what is coming next, and have them think about what they can do now to accelerate the transfer to patients." – Symposium Attendee
In addition to the scientific presentations, the symposium hosted several special guests: John Grisham was interviewed on stage by CBS correspondent Chip Reid about his involvement with focused ultrasound and writing The Tumor; Cancer Moonshot Executive Director, Greg Simon inspired the audience to push the potential of FUS; and NIH Data Expert Philip Bourne spoke on the power of data sharing to propel medical breakthroughs. READ MORE >
This Focus Feature provides highlights from the symposium. A complete scientific summary will be available later this year. All symposium abstracts are currently available online.